Board of Directors

After performing eleven years of in vitro research, safety and toxicity studies, and clinical trials, in August of 1999, a company was founded by Stephen D. Herman, M.D. to commercialize Alphamir™ and numerous other Trioxolane derivatives.  Steve Herman, MD and James Herman collectively held the proprietary rights to several patents relating to oxygenation technologies and uses, including the patent for the key ingredient in its ethical drugs, the medicinal agent Trioxolane.  Since forming Immune Technologies all rights have been legally transferred exclusively to Immune Technologies to include all marketing, sales, distribution, and manufacturing disciplines. The Company has a laboratory and chemical manufacturing facility sufficient to meet its initial manufacturing requirements.  The Company has located additional facilities in Ohio to accommodate the expected surge of new demand.  

Leonard R. Bunker, PhD – Chief  Executive Officer

Dr. Bunker is Chief Executive Officer of Immune Technologies elected by the board to lead the Company’s executive team.  His primary responsibilities include overall management of the business, fund development, and to implement planning strategies for a successful mission.  He has recently been honored to receive his Doctor of Philosophy Degree in his field of Management, Finance & Consulting.

Dr. Bunker held positions as CEO & President of Field Marketing Incorporated, and Executive Vice President of MicroNEX, Inc, where his work focused on raising capital through private placements to obtain funding for these and other start-up companies.  Prior to the formulation of Immune Technologies, he has formed five successful companies which generated positive cash flow without the necessity of borrowing any funds for their continued success.

His Business and Systems Consulting skills were applied to implementing and improving judicial systems, law firms, CPA organizations, health systems, GTE data center automated billing, private businesses and manufacturing firms. MBO and strategic planning was applied at larger more complex client sites and ROI and productivity improvement as incentive for change in client operations.

He restructured all business systems that supported the Pratt & Whitney Aircraft Group in order to meet Air Force customer service requirements. As a technically sound and productive organization, he received the award for "Best Technical Review" from the customer.  Achievements were achieved through: A quotation system for contract bidding, contract project accounting, performance measurement, spare parts order tracking and sales ordering, manufacturing and administrative applications which yielded $5.4 million saved annually.        

He developed the five year revenue plan as a direct report to the chairman of the NYSE He wrote and published a book for the NYSE for internal use concerning Post Trade Functions which addressed the clearance and settlement of trades on the “street”.  Implemented continuous net settlement (CNS) for trades and helped form the Depository Trust Corporation established for the electronic transfer of securities.

He established a manufacturing data systems division as a subsidiary for the Grumman Corporation and worked in the elite preliminary design group on the designs of advanced aircraft and rocket technology for the Department of Defense. He sold system services to commercial accounts and as an aerospace engineer, developed a portion of the reaction control system for the Lunar Module (LM) for N.A.S.A. and operated from the project office as agent for project reporting to NASA

Dr. Bunker received his M.S. Management Sciences (Honors) from L.I.U., N. Y., a B.S. in Physics from C. W. Post College, Brookville, N. Y., and an A.S. in Aircraft Technology, Academy of Aeronautics, New York. He graduated from the New York Institute of Finance, as an Allied Member of the New York Stock Exchange. Prior to this, he was an Adjunct Professor at Palm Beach Atlantic College. He is an accomplished speaker on commercial affairs.

Since 1983 Dr. Herman has devoted his life to researching prevention and treatment of cancer and AIDS.  Dr. Herman is the inventor and a principal researcher of the products and technology of Immune Technologies.   Dr. Herman has issued several patents in the field of medical research including:

“The Method for Treating Viral Infection of AIDS, Antiviral Pharmaceutical Compounds Comprising a Terpene Ozonide, Insecticidal and Repellant Compositions, Ozonides of Terpenes and their medical uses, Method for Treating Viral Infection Using Topical Administration, Antiviral Composition, Method for Treating Viral Infection Parenterally and Method of Treating a Systemic Disorder using Trioxolane and Diperoxide Compounds.”

Dr. Herman’s professional career commenced with a B.A. degree from the University of California at Los Angeles in 1957.  He received his MD from the University of Southern California (USC) in 1961.  His Rotating Internship was at Gorgas Hospital, Panama Canal Zone; and his Residency in Radiology and Nuclear Medicine, at USC, 1962-1966.  He became Board certified in Radiology and Nuclear Medicine in 1966.  He served as Lt. Commander in the U.S. Navy and was active in private practice from 1968 through 1983. 

Mr. James Herman received his BS in Chemistry from the University of California at Irvine, California, in 1982.  Since then Mr. Herman has held positions with Parker Hannifin Corporation, performing chemical analysis to diagnose hydraulic servo failure on Fa18 aircraft, Sikorsky Blackhawk’s, and Space Shuttle landing gear. He assisted in developing nonflammable hydraulic fluids for military applications.

His next position was with the Laser Precision Corporation as a senior research and development chemist. His primary objectives were to design hyphenated analytical instrumentation used in forensic analysis. From this experience he was requested to assist and instruct the F.B.I. and the D.E.A. at the F.B.I academy in Quantico, Virginia.

Following this, he accepted a position with Midwest Analytical Laboratories as director of the molecular spectroscopy laboratory.  Mr. Herman has authored numerous research papers related to the above, and has developed the manufacturing technology process relating to Immune Technologies proprietary products and assisted in formulating the Company’s product line.

Future Patents and Registrations to be filed